IP Verse

Idorsia Pharmaceuticals competitive analysis

Loading summary...

Latest patents of Idorsia Pharmaceuticals opposed by its competitors

Explore Idorsia Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 23, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP4014976
Sep 4, 2024Aprocitentan For Use In The Treatment Of Hypertension And Related Diseases In Combination With Angiotensin Converting Enzyme Inhibitor (Ace) Or Angiotensin Receptor Blocker (Arb)1

Latest publications and patents of Idorsia Pharmaceuticals New

Explore the latest publications and patents granted to Idorsia Pharmaceuticals, showcasing their recent innovations and technological advancements.

Last updated on: Oct 19, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Idorsia Pharmaceuticals

EP4014976
Sep 4, 2024Aprocitentan For Use In The Treatment Of Hypertension And Related Diseases In Combination With Angiotensin Converting Enzyme Inhibitor (Ace) Or Angiotensin Receptor Blocker (Arb)Granted And Under Opposition
EP3044211
Jan 3, 2018Antibacterial 2H-Indazole DerivativesNo Opposition Filed Within Time Limit

Latest PTAB cases involving Idorsia Pharmaceuticals

Discover the latest PTAB cases involving Idorsia Pharmaceuticals, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Idorsia Pharmaceuticals with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
IDORSIA PHARMACEUTICALS - 1 - -
ELKINGTON AND FIFE91 - - -